Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ongericimab (JS002) PFS vs Autosyringe in Healthy Subjects
NCT05859529Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ongericimab in hypercholesterolemia (2 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration at 85 days and Maximum Observed Serum Concentration at 85 days. Started May 2023; status: completed.
02
Drugs
ongericimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05859529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859529.